Research studies are enrolling now.
Those who qualify may receive*:
Plus, no cost to you.
No health insurance or referral needed.
For the safety of both staff and patients, we require that our research sites are COVID-19 SMART facilities. That means they use best practices to reduce virus exposure and are dedicated to ensuring they remain open and available for the research of investigational medications.
If you or a loved one have Parkinson’s Disease, you know that Levodopa can relieve troublesome symptoms like tremors, rigidity and stiffness. But taking Levodopa long-term can cause its own challenging motor complications. Forty percent of people taking levodopa for PD report uncontrolled, erratic movements, or dyskinesias, within 4-6 of starting the medication. After 9-15 years of treatment with levodopa, the number of people struggling with side effects such as writhing, flailing, and muscle spasms rises to 90%. These symptoms can lead to depression and isolation.
Better treatment options are needed. Right now, local clinical trials are being conducted in your area to evaluate study medications that may help minimize or stop levodopa-induced dyskinesia (LID) in Parkinson’s disease patients. If you are taking levodopa for Parkinson’s and suffer from mild or severe dyskinesia, you may qualify for these studies.
Take the next step to see if you qualify for local research studies for people with levodopa-induced dyskinesia. But don’t delay — space is limited!
Ready to get started?
Click Here.
Tell us a little bit about yourself
Answer some questions about your health
We will connect you to available studies in your area
AcurianHealth helps connect people with research studies that offer treatment under development. Since 1998, AcurianHealth has referred 1 million study candidates to 800 studies in 70 countries.
